Abstract：【Objective】 To investigate the effects of evolocumab combined with standardized conventional treatment or dapagliflozin on plaque burden and stability, lipid levels, and the incidence of major adverse cardiovascular events (MACE) in patients with atherosclerosis and concomitant diabetes. 【Methods】 A total of 124 patients with atherosclerosis complicated by diabetes, who were admitted to our hospital from January 2023 to April 2025, were selected and randomly divided into two groups, with 62 cases in each group. Patients in both groups received standardized basic treatment. Additionally, the control group was treated with dapagliflozin, while the observation group was subcutaneously injected with evolocumab. The changes in target vessel plaque volume, low-attenuation plaque volume and unstable plaque ratio were evaluated. Laboratory indicators related to blood lipids and blood glucose [low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), triglycerides (TG)] were detected. The occurrence of major adverse cardiovascular events (MACE) and medication-related adverse reactions were recorded. All those parameters were compared between the two groups. 【Results】 After 6 months of treatment, the total plaque volume, low-attenuation plaque volume and unstable plaque ratio in both groups were lower than those before treatment; furthermore, these values were lower in the observation group than the control group. The differences were statistically significant (P<0.05). Following treatment, levels of LDL-C, non-HDL-C, total cholesterol and triglycerides in both groups were lower than those before treatment; and these levels in the observation group were lower than in the control group (P<0.05). For HDL-C, neither inter-group nor intra-group comparisons revealed statistically significant differences (P>0.05). The incidence of MACE in the observation group was lower than that in the control group, a difference that was statistically significant (P<0.05). There was no statistically significant difference in the incidence of adverse events between the two groups (P>0.05). 【Conclusion】 On the basis of standardized treatment and dapagliflozin, the addition of evolocumab can reduce LDL-C and non-HDL-C, achieve significant regression of atherosclerotic plaques and improve plaque stability with safety, thereby reducing the risk of MACE such as ischemic cerebrovascular events.
赵贵生, 杨为亚. 依洛尤单抗联合标准化基础治疗及达格列净对动脉粥样硬化合并糖尿病患者斑块负荷及稳定性、血脂水平、MACE发生率的影响[J]. 医学临床研究, 2026, 43(3): 407-410.
ZHAO Guisheng, YANG Weiya. Clinical Study of Evolocumab Combined with Dapagliflozin in the Treatment of Patients with Atherosclerosis. JOURNAL OF CLINICAL RESEARCH, 2026, 43(3): 407-410.
2026, Vol. 43 
